Rhabdomyolysis secondary to drug-induced hepatitis: A case report
DOI:
https://doi.org/10.55204/scc.v1i2.e5Keywords:
Hepatotoxicity, Homeostasis, Toxicity, Muscle functionality, Enzyme deficiencyAbstract
In rhabdomyolysis, damage to muscle fibers occurs, it presents with: hyporexia, asthenia, myalgia and choluria. Among the biochemical tests, the quantification of myoglobinuria and creatine kinase (CK) is performed, which rises in the first twelve hours. Hepatocellular injury is associated with drugs. Finally, rhabdomyolysis with a mortality rate of 10%, and its severe form represents systemic complications such as renal or cardiogenic failure. A preventive and alert behavior must be created when there is consumption of especially hepatotoxic drugs, in addition to correct hydration, and hospitalization if the clinical picture warrants it, this with the aim of controlling the symptoms, and carrying out the evaluation and hydroelectrolytic correction, ruling out and preventing complications such as kidney failure
Downloads
References
Baeza-Trinidad R. Rhabdomyolysis: A syndrome to be considered. Med Clínica [Internet]. el 25 de marzo de 2022 [citado el 03 de abril de 2022];158(6):277–83. Disponible en: https://www.elsevier.es/en-revista-medicina-clinica-english-edition--462-articulo-rhabdomyolysis-a-syndrome-be-considered-S2387020622000961
Cervellin G, Comelli I, Benatti M, Sanchis-Gomar F, Bassi A, Lippi G. Non-traumatic rhabdomyolysis: Background, laboratory features, and acute clinical management. Clin Biochem [Internet]. el 1 de agosto de 2017 [citado el 16 de marzo de 2022];50(12):656–62. Disponible en: https://www.sciencedirect.com/science/article/pii/S0009912017300711
Mancebo-González A, Peñalver Jara MJ, Menéndez Naranjo L, Navarro Egea AP. Rabdomiólisis asociada al tratamiento con telbivudina: a propósito de un caso. Farm Hosp [Internet]. junio de 2017 [citado el 16 de marzo de 2022];41(3):428–30. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_abstract&pid=S1130-63432017000300428&lng=es&nrm=iso&tlng=es
Urueña T, Ríos F, Figueroa M. Rabdomiólisis por quetiapina. A propósito de un caso. Rev Educ E Investig En Emerg [Internet]. el 1 de abril de 2022 [citado el 3 abril de 2022];4(2):182–5. Disponible en: https://www.medicinadeemergencias.com/frame_esp.php?id=118
Salazar J, Mejías JC, Chávez-Castillo M, Oyaque Chimbo CE, Oyaque Chimbo TA, Zurita Gonzales TJ, et al. Rabdomiólisis: bases moleculares y presentaciones clínicas. AVFT – Arch Venez Farmacol Ter [Internet]. 2018 [citado el 16 de marzo de 2022];37(2):145–54. Disponible en: http://saber.ucv.ve/ojs/index.php/rev_aavft/article/view/15180
Cortés R, Kleinsteuber K, Vargas CP, de Los Ángeles Avaria M. Rabdomiólisis metabólica: actualización. Rev Méd Clín Las Condes [Internet]. el 1 de septiembre de 2018 [citado el 16 de marzo de 2022];29(5):553–9. Disponible en: https://www.elsevier.es/es-revista-revista-medica-clinica-las-condes-202-articulo-rabdomiolisis-metabolica-actualizacion-S0716864018301044
Lee W, Dienstag J. Hepatitis inducida por tóxicos y por fármacos. En: Jameson J, Fauci A, Kasper D, Hauser S, Longo D, Loscalzo J, editores. Harrison Principios de Medicina Interna [Internet]. 20a ed. McGraw Hill; 2018 [citado el 25 de enero de 2022]. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?bookid=2461§ionid=211917975
Cano A, Cifuentes L, Amariles P. Toxicidad hepática causada por medicamentos: revisión estructurada. Rev Col Gastroenterol [Internet]. diciembre de 2017 [citado el 25 de enero de 2022];32(4):337–48. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0120-99572017000400337&lng=en&nrm=iso&tlng=es
Ariza R, Halabe J, Lifshitz A. Intolerancia y miopatía por estatinas. Acta Méd Grupo Ángeles [Internet]. septiembre de 2020 [citado el 25 de enero de 2022];18(3):290–5. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_abstract&pid=S1870-72032020000300290&lng=es&nrm=iso&tlng=es
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Camila Estefanía Abad Espinoza, Sofía Micaela Vargas-Flores
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the moral and patrimonial rights of their works. Since Prometeo Journal is an open access publication, readers can fully or partially reproduce its content as long as they properly credit the corresponding authors and the journal itself.
Our journal is governed by the international policies SHERPA/RoMEO: Green journal: They allow the self-archiving of both the pre-print (draft of a paper) and the post-print (the version corrected and reviewed by peers) and even the final version ( layout as it will be published in the journal).
See also "Copyright and licences".
